Dr Ronald D Hall, MD | |
1098 S Mayo Trl, Suite 211, Pikeville, KY 41501-1546 | |
(606) 432-5532 | |
(606) 432-5564 |
Full Name | Dr Ronald D Hall |
---|---|
Gender | Male |
Speciality | Dermatology |
Experience | 50 Years |
Location | 1098 S Mayo Trl, Pikeville, Kentucky |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1902857980 | NPI | - | NPPES |
0758582 | Other | UMWA | |
610944002007 | Medicaid | WV | |
005940303 | Medicaid | VA | |
000000046151 | Other | KY | ANTHEM OF KY |
048726 | Other | VA | ANTHEM OF VA |
64-196850 | Medicaid | KY | |
610944002007 | Other | WV | MOUNTAIN STATE BCBS |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207N00000X | Dermatology | 19685 (Kentucky) | Primary |
174400000X | Specialist | 19685 (Kentucky) | Secondary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Modern Dermatology Of Kentucky Llc | 5496166308 | 13 |
News Archive
Genomic instability, the rearrangement of chromosomes or an abnormal number of chromosomes, is a hallmark of many human cancers.
Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Scientists are pushing ahead building 'organ-on-chips', small chips with human cells, which are useful, for example, for studying cancerous metastases in the bloodstream or the development of scar tissue, or for testing the effect of drugs or food outside a human body.
Kaiser Health News senior correspondent Mary Agnes Carey reports that, by a vote of 219-210, the House of Representatives has cleared the Senate-passed health care bill for President Barack Obama's signature. The House will now vote on a separate package of legislative changes to that bill - known as a reconciliation package - to send it to the Senate for debate this week.
› Verified 6 days ago
Entity Name | Dermatology Associates Of Pikeville, Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1811285117 PECOS PAC ID: 6709058035 Enrollment ID: O20111011000426 |
News Archive
Genomic instability, the rearrangement of chromosomes or an abnormal number of chromosomes, is a hallmark of many human cancers.
Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Scientists are pushing ahead building 'organ-on-chips', small chips with human cells, which are useful, for example, for studying cancerous metastases in the bloodstream or the development of scar tissue, or for testing the effect of drugs or food outside a human body.
Kaiser Health News senior correspondent Mary Agnes Carey reports that, by a vote of 219-210, the House of Representatives has cleared the Senate-passed health care bill for President Barack Obama's signature. The House will now vote on a separate package of legislative changes to that bill - known as a reconciliation package - to send it to the Senate for debate this week.
› Verified 6 days ago
Entity Name | Modern Dermatology Of Kentucky Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1699382507 PECOS PAC ID: 5496166308 Enrollment ID: O20201125001868 |
News Archive
Genomic instability, the rearrangement of chromosomes or an abnormal number of chromosomes, is a hallmark of many human cancers.
Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Scientists are pushing ahead building 'organ-on-chips', small chips with human cells, which are useful, for example, for studying cancerous metastases in the bloodstream or the development of scar tissue, or for testing the effect of drugs or food outside a human body.
Kaiser Health News senior correspondent Mary Agnes Carey reports that, by a vote of 219-210, the House of Representatives has cleared the Senate-passed health care bill for President Barack Obama's signature. The House will now vote on a separate package of legislative changes to that bill - known as a reconciliation package - to send it to the Senate for debate this week.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Ronald D Hall, MD Po Box 2500, Pikeville, KY 41502-2500 Ph: (606) 432-5532 | Dr Ronald D Hall, MD 1098 S Mayo Trl, Suite 211, Pikeville, KY 41501-1546 Ph: (606) 432-5532 |
News Archive
Genomic instability, the rearrangement of chromosomes or an abnormal number of chromosomes, is a hallmark of many human cancers.
Alexion Pharma International Sàrl, a subsidiary of Alexion Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration has granted a Breakthrough Therapy designation to cyclic pyranopterin monophosphate (cPMP, or ALXN1101), an enzyme co-factor replacement therapy for the treatment of patients with molybdenum cofactor deficiency type A, a severe and life-threatening, ultra-rare, genetic metabolic disorder that causes catastrophic and irreversible neurologic damage within the first weeks of life.
SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, and Edge Therapeutics, Inc., a specialty biopharmaceutical company that transforms proven, off-patent drugs into targeted, locally delivered therapies for neurological disorders, announced today that the companies have entered into a licensing agreement for drug delivery technology.
Scientists are pushing ahead building 'organ-on-chips', small chips with human cells, which are useful, for example, for studying cancerous metastases in the bloodstream or the development of scar tissue, or for testing the effect of drugs or food outside a human body.
Kaiser Health News senior correspondent Mary Agnes Carey reports that, by a vote of 219-210, the House of Representatives has cleared the Senate-passed health care bill for President Barack Obama's signature. The House will now vote on a separate package of legislative changes to that bill - known as a reconciliation package - to send it to the Senate for debate this week.
› Verified 6 days ago
Harty Elouise Ashby, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 911 Bypass Rd, Pikeville, KY 41501 Phone: 606-218-3500 | |
Dr. Brookelynn Hensley, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 911 Bypass Rd Bldg C, Pikeville, KY 41501 Phone: 606-430-2210 Fax: 606-432-2404 | |
Dr. Timothy R Lavender, D.O. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 108 N Auxier Ave, Pikeville, KY 41501 Phone: 606-432-9106 Fax: 606-432-0967 |